[go: up one dir, main page]

CN109311974A - 抗人白细胞介素-17a单克隆抗体、其制备方法和应用 - Google Patents

抗人白细胞介素-17a单克隆抗体、其制备方法和应用 Download PDF

Info

Publication number
CN109311974A
CN109311974A CN201780033670.5A CN201780033670A CN109311974A CN 109311974 A CN109311974 A CN 109311974A CN 201780033670 A CN201780033670 A CN 201780033670A CN 109311974 A CN109311974 A CN 109311974A
Authority
CN
China
Prior art keywords
monoclonal antibody
human
seq
variable region
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201780033670.5A
Other languages
English (en)
Other versions
CN109311974B (zh
Inventor
张成海
朱玲巧
郭锦林
赵杰
高宏海
马琳
党尉
杨燕
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sunshine Guojian Pharmaceutical Shanghai Co Ltd
Original Assignee
Sunshine Guojian Pharmaceutical Shanghai Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sunshine Guojian Pharmaceutical Shanghai Co Ltd filed Critical Sunshine Guojian Pharmaceutical Shanghai Co Ltd
Publication of CN109311974A publication Critical patent/CN109311974A/zh
Application granted granted Critical
Publication of CN109311974B publication Critical patent/CN109311974B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C12N2015/8518—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic expressing industrially exogenous proteins, e.g. for pharmaceutical use, human insulin, blood factors, immunoglobulins, pseudoparticles

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Physics & Mathematics (AREA)

Abstract

提供了一种抗人IL‑17A单克隆抗体、其制备方法和应用。该抗人IL‑17A单克隆抗体能够特异性与人IL‑17A结合，具有良好的抑制IL‑17A诱导的各种细胞系分泌炎性细胞因子如IL‑6等的效果，可应用于制备治疗免疫介导的炎症反应的疾病的药物。

Description

PCT国内申请，说明书已公开。

Claims (15)

  1. PCT国内申请，权利要求书已公开。
CN201780033670.5A 2016-06-12 2017-06-09 抗人白细胞介素-17a单克隆抗体、其制备方法和应用 Active CN109311974B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2016104055110 2016-06-12
CN201610405511.0A CN107488227A (zh) 2016-06-12 2016-06-12 抗人白细胞介素‑17a单克隆抗体、其制备方法和应用
PCT/CN2017/087733 WO2017215524A1 (zh) 2016-06-12 2017-06-09 抗人白细胞介素-17a单克隆抗体、其制备方法和应用

Publications (2)

Publication Number Publication Date
CN109311974A true CN109311974A (zh) 2019-02-05
CN109311974B CN109311974B (zh) 2021-07-09

Family

ID=60642645

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201610405511.0A Pending CN107488227A (zh) 2016-06-12 2016-06-12 抗人白细胞介素‑17a单克隆抗体、其制备方法和应用
CN201780033670.5A Active CN109311974B (zh) 2016-06-12 2017-06-09 抗人白细胞介素-17a单克隆抗体、其制备方法和应用

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201610405511.0A Pending CN107488227A (zh) 2016-06-12 2016-06-12 抗人白细胞介素‑17a单克隆抗体、其制备方法和应用

Country Status (5)

Country Link
US (1) US10738112B2 (zh)
EP (1) EP3470427A4 (zh)
JP (1) JP6883591B2 (zh)
CN (2) CN107488227A (zh)
WO (1) WO2017215524A1 (zh)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112250764A (zh) * 2020-10-22 2021-01-22 深圳市康瑞克生物科技有限责任公司 一种抗白细胞介素17a的单克隆抗体、其编码基因及应用
CN113817058A (zh) * 2021-09-30 2021-12-21 港科鹏禾生物(苏州)有限公司 一种抗人il-17rc的单克隆抗体及其应用
CN114920838A (zh) * 2022-03-25 2022-08-19 南京融捷康生物科技有限公司 一种抗il-17a的单域抗体及其用途
CN115461368A (zh) * 2020-04-17 2022-12-09 上海麦济生物技术有限公司 抗人白细胞介素-4受体α抗体及其制备方法和应用
WO2023083243A1 (zh) * 2021-11-11 2023-05-19 三生国健药业（上海）股份有限公司 一种抗il-17/vegf双功能融合蛋白及其用途

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108640991B (zh) * 2018-05-17 2019-09-27 江苏荃信生物医药有限公司 抗人白介素17a单克隆抗体及其应用
JP6930778B2 (ja) 2018-05-17 2021-09-01 江蘇▲筌▼信生物医薬有限公司Ｑｙｕｎｓ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｃｏ．， Ｌｔｄ． 抗ヒトインターロイキン１７ａモノクローナル抗体およびその使用
CN110551215A (zh) * 2018-05-30 2019-12-10 中山康方生物医药有限公司 抗白细胞介素-17a抗体、其药物组合物及其用途
CN111303283A (zh) 2018-12-12 2020-06-19 上海君实生物医药科技股份有限公司 抗il-17a抗体及其应用
SG11202107995SA (en) * 2019-01-31 2021-08-30 Numab Therapeutics AG Multispecific antibodies having specificity for tnfa and il-17a, antibodies targeting il-17a, and methods of use thereof
EP3689907A1 (en) * 2019-01-31 2020-08-05 Numab Therapeutics AG Antibodies targeting il-17a and methods of use thereof
CN110124030A (zh) * 2019-06-10 2019-08-16 通化东宝生物科技有限公司 一种苏金单抗注射液及其制备方法
US20220267432A1 (en) * 2019-07-30 2022-08-25 Jiangsu Hengrui Medicine Co., Ltd. Method for treating autoimmune disease by il-17 antagonist
CN110585430B (zh) * 2019-09-29 2023-09-08 华博生物医药技术（上海）有限公司 一种人源化抗人il-17a单克隆抗体的药物组合物
CN111647624A (zh) * 2020-06-10 2020-09-11 成都和同易创生物科技有限公司 Tsab人源单克隆抗体重组载体、重组抗体及其制备方法
CN114276450B (zh) * 2020-09-27 2023-08-29 江苏荃信生物医药股份有限公司 抗人il-17a单克隆抗体及其用途
CN112390890B (zh) * 2020-11-06 2022-06-24 江苏荃信生物医药股份有限公司 一种定量检测血清中抗人白介素17单克隆抗体含量的酶联免疫分析方法
CN113896793B (zh) * 2021-09-30 2023-05-26 港科鹏禾生物(苏州)有限公司 一种抗人il-17rc的单克隆抗体及其应用
CN115806615B (zh) * 2022-07-22 2023-07-14 深圳贝蒂斯生物科技有限公司 抗体和间充质干细胞外泌体制备方法以及联合治疗疾病的用途
CN115819579B (zh) * 2022-11-10 2023-11-07 浙江大学 全人源抗白介素17A单链抗体No.34及应用
CN116286667A (zh) * 2023-01-06 2023-06-23 生物岛实验室 抗人il-17a蛋白的单克隆抗体及其应用
CN117866902B (zh) * 2024-03-12 2024-06-04 北京贝来生物科技有限公司 具有抗il-17a活性的基因修饰干细胞及其制备方法以及药物组合物

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007106769A2 (en) * 2006-03-10 2007-09-20 Zymogenetics, Inc. Antibodies that bind both il-17a and il-17f and methods of using the same
WO2008134659A2 (en) * 2007-04-27 2008-11-06 Zymogenetics, Inc. Antagonists to il-17a, il-17f, and il-23p19 and methods of use
WO2009136286A9 (en) * 2008-05-05 2010-04-22 Novimmune Sa Anti-il 17a/il-17f cross-reactive antibodies and methods of use thereof
CN105073775A (zh) * 2013-02-08 2015-11-18 诺华股份有限公司 抗-il-17a抗体及其在治疗自身免疫性和炎性病症中的用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0417487D0 (en) * 2004-08-05 2004-09-08 Novartis Ag Organic compound
SI1963368T1 (sl) * 2005-12-13 2012-11-30 Lilly Co Eli Anti il protitelesa
TW200815469A (en) * 2006-06-23 2008-04-01 Astrazeneca Ab Compounds
GB0612928D0 (en) * 2006-06-29 2006-08-09 Ucb Sa Biological products
US7886449B2 (en) * 2007-02-20 2011-02-15 Electro Scientific Industries, Inc. Flexure guide bearing for short stroke stage
EP2403531A4 (en) * 2009-03-05 2013-02-27 Abbott Lab IL-17 BINDING PROTEINS
WO2012018767A2 (en) * 2010-08-05 2012-02-09 Anaptysbio, Inc. Antibodies directed against il-17
WO2014161570A1 (en) * 2013-04-03 2014-10-09 Roche Glycart Ag Antibodies against human il17 and uses thereof
HUE052184T2 (hu) * 2013-11-18 2021-12-28 Shanghai hengrui pharmaceutical co ltd IL-17A kötõanyag és felhasználásai
RU2577228C2 (ru) * 2014-03-14 2016-03-10 Закрытое Акционерное Общество "Биокад" Анти-il-17-антитела, способ их получения и способ применения

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007106769A2 (en) * 2006-03-10 2007-09-20 Zymogenetics, Inc. Antibodies that bind both il-17a and il-17f and methods of using the same
WO2008134659A2 (en) * 2007-04-27 2008-11-06 Zymogenetics, Inc. Antagonists to il-17a, il-17f, and il-23p19 and methods of use
WO2009136286A9 (en) * 2008-05-05 2010-04-22 Novimmune Sa Anti-il 17a/il-17f cross-reactive antibodies and methods of use thereof
CN105073775A (zh) * 2013-02-08 2015-11-18 诺华股份有限公司 抗-il-17a抗体及其在治疗自身免疫性和炎性病症中的用途

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115461368A (zh) * 2020-04-17 2022-12-09 上海麦济生物技术有限公司 抗人白细胞介素-4受体α抗体及其制备方法和应用
CN112250764A (zh) * 2020-10-22 2021-01-22 深圳市康瑞克生物科技有限责任公司 一种抗白细胞介素17a的单克隆抗体、其编码基因及应用
CN113817058A (zh) * 2021-09-30 2021-12-21 港科鹏禾生物(苏州)有限公司 一种抗人il-17rc的单克隆抗体及其应用
CN113817058B (zh) * 2021-09-30 2023-05-26 港科鹏禾生物(苏州)有限公司 一种抗人il-17rc的单克隆抗体及其应用
WO2023083243A1 (zh) * 2021-11-11 2023-05-19 三生国健药业（上海）股份有限公司 一种抗il-17/vegf双功能融合蛋白及其用途
CN114920838A (zh) * 2022-03-25 2022-08-19 南京融捷康生物科技有限公司 一种抗il-17a的单域抗体及其用途
CN114920838B (zh) * 2022-03-25 2023-11-24 南京融捷康生物科技有限公司 一种抗il-17a的单域抗体及其用途

Also Published As

Publication number Publication date
WO2017215524A1 (zh) 2017-12-21
US10738112B2 (en) 2020-08-11
CN107488227A (zh) 2017-12-19
EP3470427A4 (en) 2020-03-04
CN109311974B (zh) 2021-07-09
EP3470427A1 (en) 2019-04-17
US20190161544A1 (en) 2019-05-30
JP2019525730A (ja) 2019-09-12
JP6883591B2 (ja) 2021-06-09

Similar Documents

Publication Publication Date Title
CN109311974A (zh) 抗人白细胞介素-17a单克隆抗体、其制备方法和应用
JP2018183173A5 (zh)
JP2016511277A5 (zh)
JP2010500876A5 (zh)
JP2020500538A5 (zh)
JP2019522961A5 (zh)
JP2017518258A5 (zh)
PE20181336A1 (es) Anticuerpos que se unen a interleucina 8 (il-8) y sus usos
JP2014534242A5 (zh)
JP2015504306A5 (zh)
JP2016512551A5 (zh)
NZ602892A (en) Antibodies that bind human cd27 and uses thereof
JP2018527952A5 (zh)
CN115461368A (zh) 抗人白细胞介素-4受体α抗体及其制备方法和应用
JP2011514150A5 (zh)
PE20181089A1 (es) Anticuerpos anti-cd19 humano con alta afinidad
JP2016529229A5 (zh)
JP2016524463A5 (zh)
JP2013535952A5 (zh)
JP2012116856A5 (zh)
RU2016122340A (ru) Il-17a-связующий агент и способы его применения
JP2023093753A5 (zh)
JP2019521647A5 (zh)
JP2020506715A5 (zh)
JP2013509158A5 (zh)

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant